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Abstract—This study compared patterns of poststroke depres-
sion (PSD) detection among veterans with acute stroke in eight
U.S. geographic regions. Department of Veterans Affairs (VA)
medical and pharmacy data as well as Medicare data were
used. International Classification of Diseases-9th Revision
depression codes and antidepressant medication dispensing
were applied to define patients’ PSD status 12 months post-
stroke. Logistic regression models were fit to compare VA PSD
diagnosis and overall PSD detection between the regions. The
use of VA medical data alone may underestimate the rate of
PSD. Geographic variation in PSD detection depended on the
data used. If VA medical data alone were used, we found no
significant variation. If VA medical data were used along with
Medicare and VA pharmacy data, we observed a significant
variation in overall PSD detection across the regions after
adjusting for potential risk factors. VA clinicians and policy
makers need to consider enrollees’ use of services outside the
system when conducting program evaluation. Future research
on PSD among veteran patients should use VA medical data in
combination with Medicare and VA pharmacy data to obtain a
comprehensive understanding of patients’ PSD.
Key words: geographic variation, ICD-9, Medicare, poststroke
depression, PSD detection, rehabilitation, stroke, “stroke belt,”
VA, veterans.
INTRODUCTION
Depression after stroke is common. While some esti-
mates range from as low as 12 percent to as high as
80 percent [1–2], most estimates indicate that poststroke
depression (PSD) occurs among approximately 25 to
40 percent of stroke survivors [3–6]. Studies show that
PSD negatively affects patients’ functional recovery and
quality of life and is associated with increased morbidity,
mortality, and healthcare use [7–11]. Although PSD can be
effectively treated with potentially life-saving outcomes
[8,12–14], it is often underdiagnosed and undertreated
[2,13]. Currently, no documentation is available regarding
geographic variation in PSD detection. Understanding such
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fiscal year, GL = Great Lakes, ICD-9 = International Classifi-
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patient and system factors that may contribute to the under-
diagnosis and undertreatment of PSD.
Significant geographic variation in stroke epidemiol-
ogy and disparities in stroke incidence and prevalence have
been demonstrated [15–19]. In a recent study of the 2005
Behavioral Risk Factor Surveillance System (BRFSS) sur-
vey, for example, overall stroke prevalence was reported as
2.6 percent among noninstitutionalized U.S. adults and the
weighted, age-adjusted stroke prevalence varied across the
states, with the lowest in Connecticut (1.5%) and the high-
est in Mississippi (4.3%) [20]. This overall estimate of
stroke prevalence was comparable to previous study
reports [16]. The BRFSS report showed that most states
with high prevalence were clustered in the Southeast (SE)
region, except for a few additional states in other regions
(Illinois, Michigan, Missouri, Nevada, Texas, and West
Virginia) that also had high stroke prevalence (≥3.0%).
This clustering of high stroke prevalence in the SE corre-
sponded to the high stroke mortality rates previously
observed in that region, which is traditionally known as the
“stroke belt” [21–22]. No obvious simple explanation
exists for the observed variation in stroke prevalence.
Among the many different findings, the contributing fac-
tors to the variation included differences in the prevalence
of stroke risk factors (e.g., high blood pressure, high blood
cholesterol levels, diabetes, smoking, physical inactivity,
and obesity) [18–19] and sociocultural and socioeconomic
variations (e.g, cultural norms for diet and exercise,
income, social isolation, and access to healthcare and pre-
ventable services) between the areas of high and low stroke
prevalence [22]. Further studies addressing potential expla-
nations for the stroke belt are still underway, including
“The Reasons for Geographic and Racial Differences in
Stroke Study” [19].
The Department of Veterans Affairs (VA), through the
Veterans Health Administration, maintains the largest inte-
grated healthcare delivery system in the United States and
provides care to more than 5.2 million veterans each year
at more than 1,300 sites. As such, VA medical databases
provide unique resources for examining PSD detection and
comparing geographic variation in PSD. However, many
veterans covered by the VA healthcare system are also eli-
gible for healthcare plans outside the VA system and many
of them are dual- or triple-system users. For example, we
recently found that among the 1,953 VA stroke inpatients
living in the state of Florida, 30 percent were VA-only
users, 60 percent were VA-Medicare dual users, 3 percent
were VA-Medicaid dual users, and 7 percent were triple
users within the first 12 months of their acute stroke hospi-
talization [23]. Consequently, obtaining veterans’ PSD
information from non-VA sources, such as other Federal
and private plans, to gain a complete picture of their PSD
status is important. Furthermore, VA provides its enrollees
a comprehensive pharmacy benefit that could be a rich
information source for identifying patients with PSD diag-
nosed outside the VA.
The objective of this study was to use automated
administrative data from multiple sources to compare
geographic variation in PSD detection among a national
sample of VA patients diagnosed with acute stroke across
eight different geographic regions.
METHODS
Data Sources
National data were extracted from three major loca-
tions. First, we used the VA Austin Automation Center;
databases used included the Patient Treatment File Main
file and the Functional Status Outcomes Database for
inpatient care information, the Event and Visit files for
outpatient care data, and the Beneficiary Identification
and Records Locator Subsystem death file for patients’
mortality information. Second, we used the VA Phar-
macy Benefits Management Strategic Health Group; the
Pharmacy Benefit Management file was obtained for
patient antidepressant dispensing and daily dosage infor-
mation. Third, we used the VA Information Resource
Center; veteran-Medicare merged data used for this study
included the Denominator file for Medicare beneficiary’s
eligibility and sociodemographic information, the Medi-
care Provider Analysis and Review file for Medicare
inpatient care, the Carrier file for noninstitutional care,
and the Outpatient file for institutional outpatient care.
The calendar year Medicare data were converted into
equivalent fiscal years (FYs) to ensure the compatibility
of these different timeframes since the VA data are stored
by Federal FY. Further, we used a dual-system matching
strategy developed by Fleming et al. [24] to ensure that a
patient identified in one database was the same person in
the other. Full details about the matching criteria and
results are reported elsewhere [9].
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Our study cohort consisted of 5,593 VA stroke patients.
These patients had received inpatient care for acute stroke
within the VA during FY 2001, survived 60 days or more
after the index admission, and had an index length of stay
less than 365 days. An existing high-specificity algorithm
that is based on International Classification of Diseases-9th
Revision (ICD-9) stroke codes [25] and has a high predic-
tive value for identifying persons with acute stroke events
was modified by including ICD-9 code 436.xx for acute,
but ill-defined, cerebrovascular diseases [25–26].
Dependent Variables
Dependent variables were VA PSD diagnosis and
overall PSD detection. First, VA PSD diagnosis was
established if a patient had an ICD-9 depression code as a
primary or secondary diagnosis recorded in the VA inpa-
tient or outpatient databases within 12 months of the
index stroke. The ICD-9 depression codes used included
296.2x (single episode or unspecified major depressive
disorders), 296.3x (recurrent major depressive disorders),
311.xx (depressive disorder, not elsewhere classified),
300.4 (reactive depression), 309.0 (depressive reaction
acute), and 309.1 (depressive reaction prolonged). These
codes were previously reported in related studies of
depression among VA enrollees [27–28].
Second, the overall PSD detection variable was an
extension of a previous outcome measure, which provided
an even more comprehensive measurement of PSD status
of the study sample by including patients’ PSD detected
both inside and outside the VA healthcare system. The fol-
lowing databases and steps were applied in creating this
outcome measure: first, we abstracted depression-related
diagnosis codes from the VA databases as described previ-
ously; then, the same ICD-9 depression diagnosis codes
were applied to Medicare inpatient and outpatient data;
and finally, additional unique veterans were identified by
abstracting their prescription dispensing records in con-
cordance with the guideline-recommended minimum
daily dosage for antidepressant medications on the VA for-
mulary for the 12 months after the index stroke [28–29].
Table 1 shows the antidepressants and guideline-
recommended minimum daily dosages that we used. We
used the minimal daily dosage to reduce the number of
patients treated with low-dose antidepressants for pain
control or insomnia. This latter approach helped identify
the patients who were likely treated for depression but did
not have a depression ICD-9 code either in the VA medical
data or the Medicare data.
Independent Variables or Geographic Regions
In this study, we applied the classification of the U.S.
Department of Commerce Bureau of Economic Analysis
to group patients’ residential states into eight geographic
regions as shown in Table 2. These regional groupings
were based primarily on homogeneity of the states in
economic and sociodemographic characteristics, and they
are the most frequently used groupings of states in the
United States for economic analysis [30].
Sociodemographic Variables
Sociodemographic variables included age, sex, race,
marital status, priority for VA care, and mortality. Patient
priority for VA medical care was created based upon the
Means Test Indicator in the VA medical database. Full
details about the Means Test Indicator and the patient pri-
ority for VA care are reported elsewhere [9].
Table 1.
Antidepressant guideline-recommended minimum daily dosage
(milligrams/day) by patient age.
Antidepressant Patient Age≥65 <65
Sertraline 25 50
Paroxetine 10 20
Citalopram* 20 20
Fluoxetine 10 20
Fluvoxamine* 100 100
Amitriptyline NR 50
Desipramine 25 100
Doxepin 30 75
Imipramine 30 75
Nortriptyline 30 75
Protriptyline 15 15
Trimipramine 50 75
Clomipramine 75 75
Trazodone 25 150
Buproprion 50 200
Phenelzine 45 45
Tranylcypromine 20 20
Maprotiline 25 75
Nefazodone 100 200
Venlafaxine 50 75
Mirtazapine 15 15
Amoxapine 50 100
*These antidepressants were not addressed in 1997 Department of Veterans
Affairs depression guidelines; minimum daily dosage for these medications
derived from expert consensus.
NR = not recommended.
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Clinical and disease severity variables used for this
study were stroke type (ischemic vs all others), comorbid-
ity, and hospitalization admission source (hospital referral
vs all other sources) during index hospitalization. These
clinical measurements have been used previously as sever-
ity proxies in stroke-related outcome studies [31–34]. A
modified Charlson comorbidity index was used to assess
the patients’ medical comorbid conditions at the index hos-
pitalization, with higher weighted summary scores being
associated with a more severe burden of comorbidity [35].
Statistical Analysis
All data were analyzed using SAS, version 9.1 (SAS
Institute; Cary, North Carolina). Descriptive statistics
were obtained on the sociodemographic, clinical and dis-
ease severity, as well as PSD variables. Chi-square tests
on discrete variables and F-tests on continuous variables
were performed to compare these variables between the
regions. We used multivariate logistic procedures to esti-
mate the geographic variation in PSD detection, while
controlling for the sociodemographic and clinical and
disease severity factors discussed previously.
RESULTS
Table 3 shows the demographics, clinical character-
istics, and PSD detection of the study sample by region.
The distribution of the overall study sample (N = 5,593)
ranged from 2.5 percent in New England to 33.2 percent
in the SE across the eight regions. Among the demo-
graphic and clinical variables presented, significant dif-
ferences (p < 0.01) in patient age, race, marital status, and
admission source (hospital referral vs all others) between
the regions were apparent. Specifically, compared with
the others, patients in the Rocky Mountain region were
older, more likely to be white and married, and less likely
to be referred from a hospital for the index hospitaliza-
tion. In contrast, patients in the Great Lakes (GL), SE,
and Far West (FW) regions were the youngest; patients in
the Mideast (ME) were less likely to be white; patients in
the FW were less likely to be married; and patients in the
FW and GL were more likely to have hospital referrals
for the index hospitalization. In addition, significant vari-
ation (p < 0.05) was shown across the regions in unad-
justed VA PSD diagnosis and overall PSD detection 12-
months poststroke.
The results from logistic regression analyses showed
no significant geographic variation in PSD diagnosis
within the VA system (Table 4). Nevertheless, significant
geographic variation was present in overall PSD detec-
tion, after adjusting for patient demographics and clinical
factors. Specifically, patients in the ME were less likely
(adjusted odds ratio [AOR] 0.77, p < 0.01) and patients in
the Plains (PL) and Southwest (SW) were more likely
(AOR 1.23 and 1.21, respectively, p < 0.05) to be diag-
nosed with PSD than patients in the SE. Other statisti-
cally significantly factors (p < 0.01) associated with both
VA and overall PSD detection included younger age and
being nonwhite. Additional factors associated with over-
all PSD detection included high priority for VA care,
more comorbid conditions, and admission source for
index hospitalization.
It is important to note that our study cohort included
268 patients (4.8%) who were users of certain antidepres-
sants with guideline-recommended minimum daily dosages
that may have been prescribed for the management of pain
(amitriptyline and imipramine) or sleep disorders (traz-
odone, nefazodone, and mirtazapine). However, in separate
confirmation analyses, we found that the final results
remained the same, with or without these 268 patients.
Table 2.
Geographic regions defined by U.S. Department of Commerce Bureau
of Economic Analysis.
Region States
New England Connecticut, Maine, Massachusetts, New 
Hampshire, Rhode Island, Vermont
Mideast Delaware, District of Columbia,
Maryland, New Jersey, New York,
Pennsylvania
Great Lakes Illinois, Indiana, Michigan, Ohio,
Wisconsin
Plains Iowa, Kansas, Minnesota, Missouri, 
Nebraska, North Dakota, South Dakota
Southeast Alabama, Arkansas, Florida, Georgia, 
Kentucky, Louisiana, Mississippi, North 
Carolina, South Carolina, Tennessee,
Virginia, West Virginia
Southwest Arizona, New Mexico, Oklahoma, Texas
Rocky Mountain Colorado, Idaho, Montana, Utah,
Wyoming
Far West Alaska, California, Hawaii, Nevada,
Oregon, Washington
1031
JIA et al. Geographic variation in depression poststrokeTable 3.
Patient characteristics by percentage or mean ± standard deviation for entire sample (N = 5,593) and by region.
Characteristic StudySample
Regional Sample
New England Mideast Great Lakes Southeast Southwest Rocky Mountain Far West Plains
Frequency 100 2.5 12.5 13.1 33.2 15.3 3.1 11.3 9.0
Demographic
Age* 67.6 ± 11.1 68.7 ± 10.5 69.1 ± 11.4 67.0 ± 10.6 67.0 ± 11.2 67.5 ± 11.2 69.3 ± 11.0 67.2 ± 11.0 68.7 ± 10.7
Male 98.2 95.7 98.3 98.4 98.3 98.4 96.6 98.6 98.4
White* 72.3 91.9 61.8 67.4 69.2 75.0 92.4 75.8 84.8
Married* 48.0 51.8 42.5 43.5 52.1 51.9 55.4 39.3 47.1
High Priority for VA Care 92.9 89.4 90.7 92.3 93.7 92.9 92.0 94.9 92.6
12-Month Mortality 11.5 9.2 10.7 10.7 12.2 13.2 11.4 9.2 12.0
Clinical Characteristics
Ischemic Stroke 93.5 94.3 92.7 93.7 93.0 93.7 92.6 94.3 94.4
Comorbidity 0.8 ± 1.2 0.8 ± 1.0 0.9 ± 1.1 0.9 ± 1.2 0.9 ± 1.2 0.8 ± 1.1 0.9 ± 1.2 0.9 ± 1.2 0.9 ± 1.1
Hospital Referral* 4.3 3.6 1.1 5.6 4.7 2.9 0.1 7.0 3.2
Unadjusted PSD
VA PSD Diagnosis* 20.0 19.2 16.1 21.5 18.9 21.3 25.7 20.8 22.0
Overall PSD Detection* 39.1 43.3 31.0 38.0 38.7 43.1 45.1 38.3 44.5
Note: p-values were from chi-square tests for categorical variables and F-tests for continuous variables between regions.
*p < 0.05.
PSD = poststroke depression, VA = Department of Veterans Affairs.
Table 4.
Adjusted odds ratio and 95 percent confidence interval for Department of Veterans Affairs (VA) poststroke depression (PSD) diagnosis and
overall PSD detection.
Potential Factor VA PSD Diagnosis Overall PSD Detection
Region (reference = Southeast)
New England 0.97 (0.62–1.52) 1.17 (0.82–1.66)
Mideast 0.90 (0.71–1.14) 0.77 (0.64–0.94)*
Great Lakes 1.17 (0.95–1.45) 0.98 (0.82–1.17)
Plains 1.16 (0.91–1.49) 1.23 (1.00–1.51)†
Southwest 1.17 (0.96–1.44) 1.21 (1.03–1.43)†
Rocky Mountain 1.39 (0.96–2.01) 1.19 (0.86–1.64)
Far West 1.10 (0.87–1.38) 0.95 (0.78–1.15)
Age (continuous) 0.98 (0.97–0.98)* 0.99 (0.98–0.99)*
White (reference = all others) 1.55 (1.32–1.82)* 1.60 (1.41–1.82)*
Married (reference = all others) 0.92 (0.81–1.06) 1.03 (0.92–1.15)
VA Care Priority: High (reference = low) 1.03 (0.79–1.34) 1.36 (1.09–1.70)*
Ischemic Stroke (reference = all others) 1.13 (0.86–1.49) 1.19 (0.95–1.49)
12-Month Mortality: Yes (reference = no) 0.87 (0.70–1.10) 0.95 (0.80–1.14)
Comorbidity (continuous) 1.02 (0.96–1.08) 1.08 (1.03–1.13)*
Hospital Referral: Acute (reference = all others) 1.30 (0.96–1.77) 1.58 (1.21–2.06)*
*p < 0.01.
†p < 0.05.
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This study contributes to the current literature by pro-
viding a comprehensive comparison of variation in VA
PSD diagnosis and overall PSD detection across eight geo-
graphic regions of the United States. PSD is a high-volume
condition that negatively affects patients’ recovery and
quality of life. Although effective treatments for PSD are
available, PSD is often underdiagnosed and undertreated,
and the pattern of PSD diagnosis among VA healthcare
enrollees with stroke is largely unknown.
First, in this cross-sectional national study, we found
that one-third of the study cohort (patients with acute
stroke in FY 2001) were in the SE region. While this pat-
tern may appear to be consistent with the previous reports
that most states with high stroke prevalence are clustered
in the SE region [20], our intention is not to make a com-
parison for the following reasons. A lack of universal con-
sensus exists about the classification of stroke patients
mostly because of the heterogeneity of the disease. For
example, the American Heart Association and Centers for
Disease Control and Prevention consistently define stroke
under the more generic heading “cerebrovascular disease”
by using ICD-9 codes 430–438, excluding 435 for tran-
sient ischemic stroke [36–37]. In the BRFSS survey
reports [20], respondents’ stroke status was based upon
their response to the question “Has a doctor or other
health professional ever told you that you had a stroke?”
In our current study, however, we applied a stroke ICD-9
code algorithm developed by Reker and colleagues for its
high specificity and strong positive predictive value in
identifying acute stroke cases among veterans [25]. We
also modified the algorithm by including ICD-9 code
436.xx for acute, but ill-defined, cerebrovascular disease.
As a result, counting stroke patients is highly dependent
upon which ICD-9 codes are used and the fact that differ-
ent ICD-9 codes yield differing results.
Second, our logistic regression results showed no
significant geographic differences in VA PSD diagnosis,
regardless of the geographic variation in acute stroke cases
across the eight regions, even after adjusting for patients’
demographic characteristics and clinical factors. This find-
ing may reflect the results of various initiatives (e.g., Qual-
ity Enhancement Research Initiative or QUERI) that VA
has in place to enhance its quality of care and implementa-
tion of evidence-based clinical guidelines, including a
performance measure for annual depression screening for
all veterans enrolled in VA primary care clinics [38–42].
Third, in this study, we were able to link and combine
multiple sources of data (i.e., VA inpatient and outpatient
data, Medicare inpatient and outpatient data, and VA
pharmacy data) to obtain a more complete picture of
patients’ PSD status from within and outside the VA sys-
tem. With these different data sources, we found that the
patients’ VA-PSD diagnosis nearly doubled (20.0% vs
39.1%) and that patients in the SE region were more
likely to be diagnosed with PSD than patients in the ME
and less likely to be diagnosed with PSD than patients in
the PL and SW regions. This variation in overall PSD
detection among VA patients with acute stroke may not
represent PSD detection within the VA system; rather, it
reflects the difference in PSD detection beyond the VA
system across the eight regions.
Our findings, however, suggest that to gain a compre-
hensive oversight of PSD detection in VA patients, one
must evaluate non-VA data sources, since 70 percent of the
VA stroke patients were multiple healthcare system users
[23]. This study underscores the need to use other data
sources, such as Medicare data and VA pharmacy data, to
investigate stroke characteristics or outcomes within the
VA. Our findings also suggest that VA clinicians and policy
makers need to consider enrollees’ use of services outside
the VA system when conducting program evaluation and
developing interventional programs to improve care quality
and functional recovery of their patients poststroke.
It is important to note that in this study, we were
unable to obtain access to patients’ prestroke depression
status, and thus we were unable to adjust for patients’
preexisting depression in our final analyses. Although a
history of depression has been linked to an increased risk
for development of PSD, the proportion of patients with
PSD who have active depression at the time of their
stroke is not well known. Further, the impact of preexist-
ing depression on PSD detection, severity, treatment, and
outcomes is likewise not well understood. We have cho-
sen to use the term PSD in this study because we ascer-
tained depression diagnosis after an acute stroke, but
we realize the inherent ambiguity of this term. Future
studies should attempt to address this important clinical
situation.
CONCLUSIONS
Our findings indicate that clinicians in the ME region
of the country should be screening more consistently for
PSD among their stroke patients. Our study revealed that
1033
JIA et al. Geographic variation in depression poststrokefactors related to the diagnosis of PSD include younger
age, white race, higher VA care priority, heavier burden
of comorbidity, and inpatient hospital referral.
Our findings also suggest that using VA medical data
alone will likely result in an underestimate of PSD
among veterans after an acute stroke, with a twofold
increase in case ascertainment by using Medicare and VA
pharmacy information. Although PSD detection preva-
lence appears to be similar across geographic regions
when only VA data are examined, significant regional
differences are observed when both VA pharmacy and
Medicare data are included. Whether these differences
are largely explained by differences in patient sociode-
mographic characteristics of dual-users versus VA-only
users, underlying differences in the system of care, or dif-
ficulties in care coordination remains to be explored.
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